Integris Medtech IPO: dates, price band, lot size and GMP
Integris Medtech IPO opens 27 Nov – 1 Dec 2026 on the Mainboard, price band Band awaited, lot size awaited, no GMP reported yet. Allotment 2 Dec, listing 4 Dec.
Listing date: Integris Medtech IPO is scheduled to list on 4 Dec on NSE, BSE.
Updated 20 Nov 2026, 18:03 IST. Dated dealer references.
BuyUnlistedShares tracks 229 IPOs on its calendar; the Integris Medtech IPO has a price band of Band awaited, a lot of — shares and no grey-market premium reported yet as of 20 Nov 2026.
Key details
| Board | Mainboard |
|---|---|
| Issue dates | 27 Nov – 1 Dec 2026 |
| Price band | Band awaited |
| Fresh issue | ₹600 Cr |
| Subscription | — |
| Registrar | Kfin Technologies Ltd. |
| Lead managers | ICICI Securities Ltd., Axial Capital Pvt.Ltd., Citigroup Global Markets India Pvt.Ltd., IIFL Capital Services Ltd. |
| Status | Upcoming |
Timeline
- Issue opens: 27 Nov
- Issue closes: 1 Dec
- Allotment: 2 Dec
- Refunds: 3 Dec
- Demat credit: 3 Dec
- Listing: 4 Dec
Issue details
| Face value | ₹1 |
|---|---|
| Issue type | Book Build Issue |
| Listing at | NSE, BSE |
| Offer for sale (shares) | 1,08,37,266 |
| Promoter holding pre-issue | 83.24% |
| Promoters | Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh and Punita Sharma |
| Lead managers | ICICI Securities Ltd., Axial Capital Pvt.Ltd., Citigroup Global Markets India Pvt.Ltd., IIFL Capital Services Ltd. |
| Registrar phone | 040-79615565 |
| Registrar email | integris.ipo@kfintech.com |
| Company website | integrismedtech.com |
| Anchor bid date | 26 Nov 2026 |
| Anchor lock-in ends (50%) | 1 Jan 2027 |
| Anchor lock-in ends (remaining) | 2 Mar 2027 |
Reservation
| Category | Share of issue | Shares offered | Basis |
|---|---|---|---|
| QIB | — | — | Not less than 75% of the Offer |
| NII (HNI) | — | — | Not more than 15% of the Offer |
| Retail | — | — | Not more than 10% of the Offer |
Key ratios as of 31 Mar 2025
| EPS (pre-issue) | ₹6.52 |
|---|---|
| RoNW | 1.48% |
| RoCE | 14.51% |
| RoE | 5.35% |
| PAT margin | 3.72% |
| EBITDA margin | 16.26% |
| NAV per share | ₹316.09 |
Financials (₹ Cr)
| Metric | 30 Jun 2025 | FY25 | FY24 | FY23 | FY25 vs FY24 |
|---|---|---|---|---|---|
| Assets | 4,019.62 | 3,641.34 | 2,989.2 | 2,553.87 | +21.8% |
| Total Income | 508.93 | 1,959.58 | 1,582.26 | 1,369.66 | +23.8% |
| Profit After Tax | 267.57 | 70.68 | −4.88 | −40.54 | loss to profit |
| EBITDA | 78.73 | 309.4 | 190.45 | 168.82 | +62.5% |
| NET Worth | 3,889.99 | 2,752.52 | 2,681.02 | 2,629.52 | +2.7% |
| Reserves and Surplus | 2,299.84 | 1,150.74 | 1,135.71 | 1,073.12 | +1.3% |
| Total Borrowing | 793.42 | 1,729.46 | 813.1 | 556.54 | +112.7% |
About Integris Medtech
Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.
Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments.
The company's business is structured into two core divisions:
Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors.
Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America.
As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.
Objects of the issue
- Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: — ₹509.85 Cr
- The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. — ₹93.87 Cr
- The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. — ₹415.98 Cr
- General Corporate Purposes
Net proceeds: ₹1,019.7 Cr
Peer comparison
| Company | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Our Company | 5.82 | 5.73 | 316.09 | — | 1.84% | — | Consolidated |
| Poly Medicure | 34.13 | 34.11 | 278.46 | 56.02x | 12.26% | 6.87 | Consolidated |
| Laxmi Dental | 6.07 | 6.05 | 37.71 | 53.95x | 16.09% | 8.81 | Consolidated |
Notes: Closing Price per share is closing price in NSE as on October 8, 2025. P/E has been computed as market price per share as on October 8, 2025 divided by net diluted earnings per share for the year ended March 31, 2025. Basic EPS (₹) = Basic earnings per share are calculated by dividing the net restated profit or loss for the year attributable to equity shareholders by the weighted average number of Equity Shares outstanding during the year.
Risk factors (as disclosed by the company)
- We incurred restated loss for the year of ₹ 48.84 million for Fiscal 2024 and ₹ 405.41 million for Fiscal 2023, respectively
- Our business model has relied significantly on acquisitions, and continued pursuit of mergers and acquisitions may expose us to integration, execution
- We are required to obtain, renew or maintain certain statutory and regulatory permits and approvals for operating our business
- Self-corrective quality issues related product holds and recalls, mandatory product recalls, safety alerts
- Inability to preserve and extend existing relationships with distributors, customers
- Intense competition and pricing pressure across our key businesses, i.e., medical devices, clinical diagnostics
- Inability to keep pace with rapid technological advancements and changing customer preferences may erode our competitive positioning and result in revenue…
- Risks related to temperature-sensitive inventory, supply chain failures — reagents and lab solutions that require temperature-controlled storage and transportation (cold chain logistics).
From the RHP (risk factors pages 25–46). Headings shortened; the wording is the company’s. Not a recommendation.
Offer documents: DRHP (PDF)
Track this issue
- Integris Medtech IPO GMP today and trend
- Integris Medtech IPO subscription status, day by day
- Integris Medtech IPO allotment status and how to check
Frequently asked questions
When does the Integris Medtech IPO open and close?
The issue is scheduled for 27 Nov – 1 Dec 2026.
What is the Integris Medtech IPO price band?
The price band is Band awaited per share.
When will Integris Medtech list?
The tentative listing date is 4 Dec on the main board.
How do I apply for the Integris Medtech IPO?
Apply through your broker or bank using ASBA or UPI within the issue window; the amount stays blocked in your account until allotment. BuyUnlistedShares does not take applications; it tracks the issue and the unlisted price before it.
Sources
- Draft red herring prospectus (DRHP), Integris Medtech · as filed with SEBI · sebi.gov.in
- Registrar allotment page, Kfin Technologies Ltd. · allotment 2 Dec · ipostatus.kfintech.com
- NSE public issues page · listing 4 Dec · nseindia.com
- BSE public issues page · listing 4 Dec · bseindia.com
- Integris Medtech company website · integrismedtech.com
- BuyUnlistedShares IPO record: GMP, subscription and allotment, dated daily · GMP as of 20 Nov, 08:40 · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “Integris Medtech IPO”, https://buyunlistedshares.com/ipo/integris-medtech-ipo, as of 20 Nov 2026.
Other IPOs on the calendar
- Crystal Crop Protection IPO · 18 – 20 Nov 2026
- Mahanadi Coalfields IPO · 19 – 23 Nov 2026
- Watrana Rentals IPO · 19 – 23 Nov 2026
- Shree Siddhivinayak Greentech Industries IPO · 25 – 27 Nov 2026
- Foodlink F&B Holdings IPO · 26 – 30 Nov 2026
- Monomark Engineering IPO · Dates awaited
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP, in the market since 2002. Reviewed by the BuyUnlistedShares desk before publishing. Data as of 20 Nov 2026.
Guides for IPO applicants and pre-IPO holders
- The risks of buying unlisted and pre-IPO shares in India
- Unlisted Shares Lock-In Period: What Every Investor Must Know (2026)
- What Happens to Your Unlisted Shares After the IPO? Lock-In Periods Explained
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Community · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform
Part of the Gayatri Financial Synergy group (gayatrifin.com): AMFI-registered mutual fund distributor, Faridabad, since 2002.
BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59
